Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 5/20 | 0.65 |
| ▸ | BACE1 | P56817 | 10/20 | 0.57 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | ACE | P12821 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2507078 | 1.00 | REN (0.65) | RENBACE1BACE2MAPK1ACE | |
| SCHEMBL11105884 | 0.94 | ACE (0.61) | RENBACE1ACE | |
| SCHEMBL16576286 | 0.92 | REN (0.64) | RENBACE1BACE2 | |
| SCHEMBL17629479 | 0.91 | REN (0.71) | RENMAPK1ACE | |
| SCHEMBL21244275 | 0.91 | REN (0.71) | RENMAPK1ACE | |
| SCHEMBL3499528 | 0.91 | REN (0.71) | RENMAPK1ACE | |
| SCHEMBL3824374 | 0.91 | REN (0.71) | RENMAPK1ACE | |
| SCHEMBL19341935 | 0.91 | REN (0.71) | RENMAPK1ACE | |
| SCHEMBL7815002 | 0.90 | REN (0.61) | RENBACE1ACE | |
| SCHEMBL9101393 | 0.90 | REN (0.73) | RENMAPK1ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049899-A2 | METHODS TO PREVENT AND TREAT DISEASES | Elgebaly, Salwa A. (US) | 2009-04-22 | — | — | EP | claimed |
| US-20080008694-A1 | METHODS TO PREVENT AND TREAT DISEASES | NOUR HEART, INC. | 2008-01-10 | — | — | US | claimed |
| WO-2008005084-A2 | METHODS TO PREVENT AND TREAT DISEASES | ELGEBALY SALWA A (US) | 2008-01-10 | — | — | WO | claimed |
| US-20160213742-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | CIDARA THERAPEUTICS, INC. (US) | 2016-07-28 | — | — | US | disclosed |
| US-8288350-B2 | Methods to prevent and treat diseases | NOUR HEART, INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-20110245149-A1 | METHODS TO PREVENT AND TREAT DISEASES | NOUR HEART, INC. (US) | 2011-10-06 | — | — | US | disclosed |
| EP-2049899-A2 | METHODS TO PREVENT AND TREAT DISEASES | Elgebaly, Salwa A. (US) | 2009-04-22 | — | — | EP | disclosed |
| US-20080008694-A1 | METHODS TO PREVENT AND TREAT DISEASES | NOUR HEART, INC. | 2008-01-10 | — | — | US | disclosed |
| WO-2008005084-A2 | METHODS TO PREVENT AND TREAT DISEASES | ELGEBALY SALWA A (US) | 2008-01-10 | — | — | WO | disclosed |
| EP-1007106-A1 | COMBINATORIAL LIBRARY | RESOLUTION PHARMACEUTICALS INC. (CA) | 2000-06-14 | — | — | EP | disclosed |
| WO-1999010016-A1 | COMBINATORIAL LIBRARY | RESOLUTION PHARMACEUTICALS INC. (CA) | 1999-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160213742-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | FPR1, FPR3, FPR2 | REN 4702/4885BACE1 432/4885BACE2 1341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.